Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ ACD Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA568757
Description
This target displays homology in the following species: Cow: 83%; Dog: 85%; Guinea Pig: 85%; Horse: 85%; Human: 85%; Mouse: 100%; Rat: 93%.
This gene encodes a uridine 5' -monophosphate synthase. The encoded protein is a bifunctional enzyme that catalyzes the final two steps of the de novo pyrimidine biosynthetic pathway. The first reaction is carried out by the N-terminal enzyme orotate phosphoribosyltransferase which converts orotic acid to orotidine-5' -monophosphate. The terminal reaction is carried out by the C-terminal enzyme OMP decarboxylase which converts orotidine-5' -monophosphate to uridine monophosphate. Defects in this gene are the cause of hereditary orotic aciduria. Alternate splicing results in multiple transcript variants.
Specifications
ACD | |
Polyclonal | |
Unconjugated | |
ACD | |
Acd; ACD shelterin complex subunit and telomerase recruitment factor; ACD, shelterin complex subunit and telomerase recruitment factor; adrenocortical dysplasia; adrenocortical dysplasia homolog; adrenocortical dysplasia homolog (mouse); adrenocortical dysplasia protein; Adrenocortical dysplasia protein homolog; PIP1; POT1 and TIN2-interacting protein; PTOP; TIN2 interacting protein 1; TINT1; TPP 1; TPP I; TPP1; TPPI | |
Rabbit | |
Affinity Chromatography | |
RUO | |
497652 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Western Blot | |
0.5 mg/mL | |
PBS with 2% sucrose and 0.09% sodium azide | |
Q5EE38 | |
ACD | |
synthetic peptide directed towards the c terminal region of mouse ACD. | |
100 μL | |
Primary | |
Mouse | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction